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transcription factor 2, an osteogenic gene, was up-regulated 
at 20 weeks.
Conclusions In our tendon defect model, cells participat-
ing in the tendon healing process appeared to differentiate 
toward tenocyte lineage only in the early phase, and chon-
drogenesis seemed to occur from the early phase onward. 
To improve tendon repair, it will be necessary to promote 
and maintain tenogenesis and to inhibit chondrogenesis, 
especially in the early phase, in order to avoid erroneous 
differentiation of stem cells.
Introduction
The healing mechanism of ruptured or injured tendons is 
poorly understood. Even over periods of long-term obser-
vation, the structure and strength of repaired tissue does 
not show full recovery and a return to normal. Many 
authors have studied tendon healing [1, 2]. Sharma et al. 
[3] reported that tendon healing occurred in three overlap-
ping stages: the inflammatory stage (from injury to a few 
days after injury), the remodeling stage (a few days to 
6 weeks after injury), and the modeling stage (6 weeks to 
over 1 year after injury). One of the early events of wound 
healing is angiogenesis, in which neovascularization 
prompts the delivery of inflammatory cells and fibroblasts 
to the wound site. In wounds, hypoxia-inducible factor-1 
(HIF1) plays an important role in the intracellular hypoxic 
response. HIF1 is a heterodimeric transcription factor com-
posed of an alpha and a beta subunit. In cultured fibro-
blasts undergoing cyclical strain, overuse has been shown 
to strongly induce the alpha subunit of HIF1 (HIF1A) [4]. 
HIF1 is an important up-regulator of vascular endothelial 
growth factor (VEGF), which promotes the formation of 
new blood vessels after tendon injury [5–9].
Abstract 
Background The healing mechanism of ruptured or 
injured tendons is poorly understood. To date, some line-
age-specific factors, such as scleraxis and tenomodulin, 
have been reported as markers of tenocyte differentiation. 
Because few studies have focused on tenocyte lineage-
related factors with respect to the repaired tissue of heal-
ing tendons, the aim of this study was to investigate their 
expression during the tendon healing process.
Methods Defects were created in the patellar tendons of 
rats, and the patellae and patellar tendons were harvested 
at 3 days and at 1, 2, 3, 6, 12, and 20 weeks after surgery. 
They were studied using micro-computed tomography, and 
paraffin-embedded sections were then prepared for histo-
logical evaluation. Reverse transcription-polymerase chain 
reactions were performed to analyze the expression of 
genes related to the tenocyte lineage, chondrogenesis, and 
ossification.
Results Repaired tissue became increasingly fibrous over 
time and contained a greater number of vessels than nor-
mal tendons, even in the later period. Safranin O staining 
revealed the existence of proteoglycan at 1 week and its 
persistence through 20 weeks. Ossification was detected 
in all tendons at 12 weeks. The expression of tenocyte lin-
eage-related genes was high at 1 and 2 weeks. Chondro-
genic genes were up-regulated until 6 weeks. Runt-related 
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In a tendon window injury model, Lui et al. [10, 11] 
reported that fibrous tendinous tissue as well as chondro-
cyte phenotype and ectopic ossification were observed in 
collagenase-damaged tendons, and speculated that errone-
ous differentiation of stem cells may have occurred. Some 
stem cells have been demonstrated to form tendinous tissue 
in vitro and in vivo. These cells, which have been detected 
in the synovium, bone marrow, adipose, and tendon, are 
reported to be multipotent [12]. They are believed to play 
a role in tendon healing, although it remains unknown 
whether they participate in healing responses for tendon 
injuries in vivo. To date, some lineage-specific factors, 
including scleraxis (SCX) and tenomodulin (TNMD), 
have been reported as markers of tenocyte lineage differ-
entiation. SCX is a member of the basic helix-loop-helix 
family of transcription factors [13], and is expressed in ten-
don progenitors in the embryonic phase. It also positively 
regulates the expression of TNMD in the tenocyte lineage 
[14]. TNMD is a type II transmembrane protein that is spe-
cifically expressed in dense connective tissue, including 
tendons and ligaments [15, 16]. Mice lacking TNMD dis-
play severely reduced tenocyte proliferation in tendons at 
birth and a disrupted collagen fibril structure in adulthood 
[17]. Some chondrogenic factors have been detected in 
Achilles [18] and rotator cuff tendinopathy [19]. Research 
has revealed that SRY (sex-determining region Y)-box 9 
(SOX9) is essential for chondrocyte differentiation and car-
tilage formation [20]. Type II collagen (Col2) and aggrecan 
(AGG) are two major components of the cartilage matrix, 
and their expression is regulated by SOX9 [21, 22]. In 
addition to chondrometaplasia, ectopic ossification can be 
detected in some damaged tendons [10, 11]. Type X col-
lagen (Col10) is a marker of hypertrophic chondrocytes 
and an indicator of endochondral ossification [23]. In addi-
tion, runt-related transcription factor 2 (RUNX2) is a key 
lineage-specific regulator of progenitor cell growth and dif-
ferentiation, which stimulates osteoblast maturation during 
bone formation [24].
The ability to improve the properties of repaired tissue is 
needed in order to promote better outcomes in the treatment 
of tendon disorders, as this tissue is produced and inter-
posed at the injury site irrespective of whether the treat-
ment for tendon ruptures is surgical or conservative. Few 
studies have focused on factors related to tenocyte lineage 
in repaired tissue of healing tendons. The aim of this study, 
therefore, was to analyze the expression of lineage-specific 
genes related to tenocytes, chondrogenesis, and ossifi-
cation in repaired tissue at tendon defect sites using a rat 
model. Our hypotheses are as follows. First, even if angi-
ogenesis occurs in the early phase of tissue repair at sites 
of surgically created tendon defects, the number of vessels 
would decrease to levels observed in normal tendons in the 
later period. Second, fibrous tendinous tissue with some 
chondrogenic change would arise, and remodeling toward 
normal tendinous tissue would occur in the later period. In 
addition, factors related to the tenocyte lineage would be 
kept up-regulated for a longer period to reflect the remod-
eling of repaired tissue.
Methods
Tendon defect model
Forty-two male Sprague Dawley rats (12–15 weeks old, 
380–470 g) were purchased from Charles River Labora-
tories Japan, Inc. The rats were anesthetized by intraperi-
toneal administration of 50 mg/kg pentobarbital (Nemb-
utal, Sumitomo Dainippon Pharma, Japan). Skin incisions 
were made longitudinally over the patellar tendons, and 
the synovium over the patellar tendons was removed. On 
the treated side, 2-mm2 defects were created in the patel-
lar tendons. Marker sutures (6-0 nylon sutures) were 
inserted into the four corners of the defects (Fig. 1). On 
the contralateral side of the knees, the patellar tendons 
were explored only as sham operations. Skin incisions 
were closed with running 6-0 nylon sutures. The patellae 
and patellar tendons were harvested at 3 days and at 1, 
2, 3, 6, 12, and 20 weeks after surgery (n = 6, each) and 
then immersed in RNAlater (Qiagen, Hilden, Germany) 
solution in microtubes. They were studied using micro-
computed tomography (micro-CT). Following this, they 
were longitudinally divided down the center. Half of the 
tissue specimens were used to prepare paraffin-embedded 
sections (Fig. 1a), and the remaining were used to extract 
total ribonucleic acid (RNA) for performing reverse tran-
scription-polymerase chain reactions (RT-PCR) (Fig. 1b). 
The experimental design was approved by our institu-
tional animal study committee.
Fig. 1  Tendon defect model. After harvesting, a half of the speci-
mens were used to prepare paraffin-embedded sections, and b total 
ribonucleic acid (RNA) was extracted from repaired tissue of the 
remaining specimens
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General histology
Half of the patellae and patellar tendons were fixed with 
10 % buffered formalin, and were then decalcified with 
ethylenediaminetetraacetic acid (EDTA) and embedded in 
paraffin. Next, 5-µm sections were prepared in the direction 
of the longitudinal axis, and the sections were deparaffi-
nized and stained using hematoxylin-eosin, Van Gieson’s, 
and safranin O staining protocols. A BZ-9000 microscope 
(Keyence Corporation, Osaka, Japan) was used to acquire 
digital micrographs. The number of vessels within a section 
area of 1 mm2 was counted.
Real-time RT-PCR
The remaining half of the patellar tendon tissue samples were 
immersed in RNAlater solution (Qiagen, Hilden, Germany), 
and the repaired tissue was excised from the area within 
marker sutures. The average (standard deviation: ±SD) 
weight of the samples was 14.3 (±6.0) mg for the treated 
tendons and 13.6 (±3.9) mg for the sham group. The sam-
ples were snap-frozen using liquid nitrogen and ground into 
powder. Total RNA was extracted using the RNeasy Mini 
Kit (Qiagen), according to manufacturer instructions. A total 
of 50 µl of water was used for the final extraction from each 
RNeasy Mini spin column. RNA samples were then quanti-
fied with Eppendorf BioPhotometer plus (Eppendorf, Ham-
burg, Germany) and TrayCell with a 1-mm cap (Hellma, 
Müllheim, Germany). The average (±SD) concentrations of 
the RNA samples were 40.4 (±28.8) µg/ml from the treated 
tendons and 15.5 (±7.9) µg/ml from the sham group. RNA 
samples were reverse-transcribed to synthesize single-
stranded complementary deoxyribonucleic acid (cDNA) 
samples using the High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA), according to 
manufacturer instructions. A total of 10 µl of RNA samples 
was used for a 20-µl reaction. The genes of interest were as 
follows: HIF1A, VEGF (angiogenesis-related); SCX, TNMD, 
and type I collagen (Col1) (tenocyte lineage related); SOX9, 
AGG, and Col2 (chondrogenesis related); and RUNX2 
and Col10 (osteogenesis related). The sequences of primer 
pairs for messenger RNA (mRNA) of the target genes were 
selected from databases such as UniSTS (http://www.ncbi.
nlm.nih.gov/unists) or were designed using the Primer3Web 
(http://primer3.sourceforge.net/) software and synthesized by 
Nihon Gene Research Laboratories, Japan. The primer pair 
of HIF1A was designed and synthesized by Sigma-Aldrich 
Japan (Table 1). A total of 1 µl of the cDNA samples and 
10 pmol of primer pairs was mixed using the LightCycler 
480 DNA SYBR Green I Master Mix (Roche Diagnostics, 
Basel, Switzerland) for 20 μl reactions, following the recom-
mended protocol. Real-time quantitative PCR was performed 
using a LightCycler 480 II (Roche Diagnostics) following the 
recommended protocol for the SYBR Green I Master Mix, 
and the threshold cycle (Ct) of each gene was determined. In 
brief, PCR cycles consisted of denaturation at 95 °C for 10 s, 
annealing at 60 °C for 10 s, and extension at 72 °C for 10 s. 
If contamination was suspected in the melting curve analy-
sis, the measurement was repeated. Given the limited amount 
of sample material, only single measurements were carried 
out. Some PCR products were diluted 10-fold, from 10−5 to 
10−8µg/ml, and used as standards. PCR of these products was 
performed to obtain standard curves, and efficiency values 
were calculated from the slopes of the products using Light-
Cycler 480 software (Roche Diagnostics) (Table 1). The rela-
tive expression ratio of the target gene was calculated using 
the Pfaffl method [25], and the ratio was expressed in com-
parison to a reference gene.
Etarget is the real-time PCR efficiency of a target gene 
transcript; Eref is the real-time efficiency of a reference 
ratio =
(Etarget)�Cttarget(control − sample)
(Eref)�Ctref (control − sample)
Table 1  Primer sequences for RT-PCR
HIF1A alpha subunit of hypoxia-inducible factor-1, VEGF vascular 
endothelial growth factor, SCX scleraxis, TNMD tenomodulin, Col1 
type I collagen, SOX9 SRY (sex-determining region Y)-box 9, AGG 
aggrecan, Col2 type II collagen, RUNX2 runt-related transcription 
factor 2, Col10 type X collagen, GAPDH glyceraldehyde-3-phos-
phate dehydrogenase
Sequence Efficiency
HIF1A Forward GAAAGAGCCCGATGCCCTGA 1.88
Reverse TTGGTCTTCAGTTTCCGTGT-
CATC
VEGF Forward TTCAGAGCGGAGAAAGCATT 1.82
Reverse GAGGAGGCTCCTTCCTGC
SCX Forward TCATCCCGACCGAGCCAGCA 1.96
Reverse CCGCAGGCTTCACCCACCAG
TNMD Forward CCTACTGCTACCAAGGAGGTCG 1.95
Reverse AGGATAGGCTACTTGGACGCAA
Col1 Forward CCGTGCTTCTCAGAACATCA 1.84
Reverse CTTGCCCCATTCATTTGTCT
Sox9 Forward AGACCAGTACCCGCATCT 1.96
Reverse CGCTCCGCCTCCTCCAC
AGG Forward TTGGAGCCGGAGACGACAGA 1.81
Reverse AGAGGCAGAGGGACTTTCGGT
Col2 Forward TTCCTCCGTCTACTGTCCACTGA 1.97
Reverse CTACATCATTGGAGCCCTGGAT
RUNX2 Forward CCGCACGACAACCGCACCAT 1.89
Reverse CGCTCCGGCCCACAAATCTC
Col10 Forward TTGACAAAGATGCCAGAAA 1.79
Reverse TACAAGGTGCTTTACCACAGCC
GAPDH Forward GCAACTCCCATTCTTCCACC 2.00
Reverse CACCCTGTTGCTGTAGCCATA
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gene transcript. In this study, the glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) gene was used as a refer-
ence gene. ΔCttarget is the Ct deviation of the value of [con-
trol (the sample of the sham side) − sample (the sample of 
the treated side)] of the target gene transcript. ΔCtref is the 
Ct deviation of the value of (control − sample).
Micro-CT
Samples of the patellae and patellar tendons were immersed 
in RNAlater solution in microtubes. Micro-CT of these sam-
ples was then performed using the R_mCT System (Rigaku 
Corporation, Japan). The X-ray tube voltage was set at 90 kV, 
and the current was set at 150 µA. A sample gantry diameter 
of 55 mm was selected for 10× magnification. The lower half 
of the patella and the treated area of the patellar tendon were 
included in the region of interest. The volume data were con-
verted into multi-page TIFF files using the ATLAS Volume 
file tiff converter. The multi-page TIFF files were opened 
using ImageJ (National Institutes of Health Research Ser-
vices Branch) software. Grayscale images in the multi-page 
TIFF files were converted to black-and-white binary images, 
with the threshold set at 22000/38049. Three-dimensional 
images were reconstructed using the3D Viewer ImageJ plugin 
(http://3dviewer.neurofly.de/). Volumes of ectopic ossification 
were calculated using the Sync Measure 3D plugin.
Statistics
The number of vessels for each time point was presented as 
the average ± SD. The numbers of all time points were com-
pared by one-way analysis of variance (ANOVA) using PASW 
Statistics software (version 18.0; IBM Corporation, Armonk, 
NY, USA). The Bonferroni test was used as a post hoc test. 
Gene expression was analyzed using RT-PCR. ΔCt of the tar-
get gene was calculated using the following formula: Ct of the 
target gene − Ct of the internal reference gene (GAPDH). At 
each time point, ΔCt of the treated side was compared with 
that of the sham side using 2 way-ANOVA with ANOVA4 
(http://www.hju.ac.jp/~kiriki/anova4/about.html). The p value 
was set at 0.05. The relative expression ratio of the target gene 
was calculated using the Pfaffl method, and indicated as the 
average ± SD. Volumes of ectopic ossification calculated 
from micro-CT are presented as the average for each time 
point, with the range provided in parentheses.
Results
General histology
On the sham side, the patellar tendons largely comprised 
dense connective tissue. The cells in the tendon resided 
between collagen fibers, and the number of cells was small 
(Fig. 2a). Vessels were present in the tissue around the ten-
don mid-substance, but not within it. After 3 days, the defects 
were filled with repaired tissue, along with a large number of 
cells and a few fibrous components (Fig. 2b). At 1 week, more 
fibrous components could be observed (Fig. 2c). While the tis-
sue became more fibrous over time, its cellularity decreased 
(Fig. 2c–h). On the sections with Van Gieson’s staining, col-
lagen fibers were stained red in the sham group (Fig. 3a). At 
3 days and 1 and 2 weeks, the regenerated tissue at the tendon 
defect sites was not stained red (Fig. 3b–d), but was partially 
stained red at 3 weeks (Fig. 3e) and completely stained at 
6 weeks (Fig. 3f). Tendons on the sham side were not stained 
with safranin O (Fig. 4a). After 1 week, sections of the treated 
tendons stained with safranin O (Fig. 4c) revealed the appear-
ance of chondrometaplasia. Interestingly, the stained area 
included the treated site and the surrounding tissue (Fig. 4c–f). 
At 6 weeks, chondrocyte-like oval-shaped cells were detected 
in the safranin O-stained area (Fig. 4e). At 12 and 20 weeks, 
all rats exhibited ectopic ossification in the patellar tendons 
(Figs. 2g–h, 4g–h). The center of ossification appeared to be at 
the tendon defect site, although it extended beyond the treated 
site. There appeared to be a transitional zone of bone, carti-
lage, and fibrous tissue around the areas of ossification.
Angiogenesis
The number of vessels within a 1-mm2 area of the repaired 
tissue was determined (Fig. 5a), and showed a peak at 
3 days (64.0 ± 32.0 vessels). At 2 weeks, the number was 
reduced (26.7 ± 5.7 vessels), and it did not change remark-
ably thereafter. However, the number of vessels remained 
higher than that of the sham side.
Angiogenesis-related factors
RT-PCR revealed that VEGF mRNA was up-regulated in 
the treated group compared to the sham group at 2 weeks 
(5.0 ± 5.3-fold, p < 0.05). HIF1A mRNA was also signifi-
cantly up-regulated at 2 weeks (4.0 ± 1.3-fold, p < 0.05) 
(Fig. 5b).
Tenocyte lineage-related factors
SCX expression in the treated group compared to the sham 
group peaked at 2 weeks (7.8 ± 12.9-fold, p = 0.16); 
however, its levels declined at 3 weeks and remained low 
until 20 weeks. TNMD mRNA expression was signifi-
cantly up-regulated at 1 (13.1 ± 23.9-fold, p < 0.05) and 2 
(8.3 ± 10.1-fold, p < 0.05) weeks. Col1 was up-regulated 
at 1 (139.6 ± 295.3-fold, p < 0.05), 2 (13.8 ± 3.7-fold, 
p < 0.05), 6 (9.9 ± 9.1-fold, p < 0.05), and 20 (9.5 ± 7.9-
fold, p < 0.05) weeks (Fig. 6a).
384 T. Omachi et al.
1 3
Fig. 2  Hematoxylin-eosin-stained sections. The patellae are located 
on the right and the tendons (including repaired tissue) on the left. 
The location of the defects are indicated with black double-ended 
arrows. Vessels are indicated with green arrowheads. a On the sham 
side, vessels were present in the tissue around the tendon mid-sub-
stance, but not within it. b At 3 days, the defects were filled with 
repaired tissue, along with many cells and vessels. c–g While the tis-
sue became more fibrous over time, its cellularity decreased. g–h At 
12 and 20 weeks, ectopic ossification was present in all rats had
Fig. 3  Sections with Van Gieson’s stain. a Collagen fibers were stained red on the sham side. b–d At 3 days and 1 and 2 weeks, the regenerated 
tissue at the tendon defect sites were not stained red. e–f They were partly stained red at 3 weeks and completely stained at 6 weeks
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Chondrogenic factors
SOX9 mRNA expression was up-regulated in the 
treated group compared to the sham group at 1 week 
(7.1 ± 3.3-fold, p < 0.05), and remained up-regulated for 
6 weeks (17.9 ± 22.3-fold, p < 0.05). AGG was up-regu-
lated at 1 week (66.1 ± 56.7-fold, p < 0.05), and remained 
up-regulated for 3 weeks (22.0 ± 3.6-fold, p < 0.05). 
Fig. 4  Safranin O-stained sections. a Tendons on the sham side 
were not stained with safranin O. c After 1 week, staining could be 
seen on sections of the treated tendons, including the injured site 
and surrounding tissue. f At 6 weeks, chondrocyte-like oval-shaped 
cells were detected, indicated by black arrowheads. g–h At 12 and 
20 weeks, there appeared to be a transitional zone of bone, cartilage, 
and fibrous tissue around areas of ectopic ossification
Fig. 5  Angiogenesis-related 
factors. a The number of ves-
sels within a 1-mm2 area of 
repaired tissue peaked at 3 days, 
with some vessels remaining 
even in the later period. There 
were no vessels in the tendon 
mid-substance on the sham 
side. b Reverse transcription-
polymerase chain reaction 
(RT-PCR) detected messenger 
RNA (mRNA) upregulation of 
the alpha subunit of hypoxia-
inducible factor-1 (HIF1A) and 
vascular endothelial growth 
factor (VEGF) at 2 weeks
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Significant upregulation of Col2 was detected at 12 weeks 
(25.8 ± 1.5-fold, p < 0.05) (Fig. 6b).
Osteogenesis related factors
RUNX2 mRNA expression was up-regulated in the treated 
group compared to the sham group at 2 (3.7 ± 2.3-fold, 
p < 0.05), 3 (2.6 ± 1.4-fold, p < 0.05), and 20 (24.1 ± 4.7-
fold, p < 0.05) weeks. No significant change was observed 
in Col10 mRNA expression (Fig. 6c).
Ossification
Micro-CT revealed no ectopic bone formation on the sham 
side. On the treated side, ectopic bone was not detected 
at 3 weeks (Fig. 7a). At 6 weeks, ectopic ossification 
was observed in two cases (Fig. 7b). The volume of the 
ossification was 0.28 mm3 (range 0–0.60 mm3) (Fig. 7e). At 
12 and 20 weeks, all tendons showed ectopic ossification 
(Fig. 7c, d). The volume of this ossification was 1.22 mm3 
(range 0.74–2.01 mm3) at 12 weeks and 16.96 mm3 (range 
9.76–26.95 mm3) at 20 weeks (Fig. 7e).
Discussion
One of the early events of wound healing is neovasculari-
zation, which prompts the delivery of inflammatory cells 
and fibroblasts to the wound site. In this study, the num-
bers of vessels in repaired tissue were increased at 3 days 
and 1 week. The mRNA expression of HIF1A and VEGF 
in our RT-PCR assays was significantly up-regulated in 
the treated group compared to the sham group at 2 weeks, 
after which time no upregulation was detected. A normal 
Fig. 6  mRNA expression of lineage-specific factors. a Tenocyte lin-
eage-related factors. mRNA expression of scleraxis (SCX) peaked at 
2 weeks. Tenomodulin (TNMD) was up-regulated at 1 and 2 weeks. 
Type I collagen (Col1) was significantly up-regulated at 1 and 
2 weeks. b Chondrogenesis-related factors. SRY (Sex-determining 
region Y)-box 9 (SOX9) was up-regulated at 1 week, and this upreg-
ulation persisted for 6 weeks. Aggrecan (AGG) was up-regulated at 
1, 2, and 3 weeks. Significant mRNA upregulation of type II colla-
gen (Col2) was detected at 12 weeks. c Osteogenesis-related factors. 
Runt-related transcription factor 2 (RUNX2) was up-regulated at 12 
and 20 weeks
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tendon consists of dense connective tissue, with poorly 
formed blood vessels. It was expected that the number 
of vessels would fall to normal tendon levels in the later 
period. However, repaired tissue consisted of some vessels 
even in the later period. This could be one of the reasons 
for the incomplete recovery of repaired tissue. Vasculari-
zation into cartilage is a key mechanism for bone forma-
tion [26, 27], and sustained vascularity may be related to 
ectopic ossification.
Some types of mesenchymal stem cells are known to 
concentrate in tendon defect sites [28], and their differen-
tiation patterns should determine the fate of the repaired 
tissue. However, the precise origins of these cells in the 
repaired tissue of damaged tendons have not been deter-
mined. If the tenocyte lineage-specific factors were up-
regulated in the very early period, we could speculate that 
tenocytes or tendon stem cells were the main component 
of the stem cells for the formation of the regenerated tis-
sue. But they were not up-regulated at 3 days, and thus the 
source of the stem cells was not clear from the results of 
this study. It was also expected that the gene expression of 
tenocyte lineage-related factors would remain up-regulated 
during tendon repair. In this study, the mRNA expression 
of SCX peaked at 2 weeks, and that of TNMD was signifi-
cantly up-regulated at 1 and 2 weeks. Contrary to expecta-
tions, the gene expression of tenocyte lineage-related fac-
tors was up-regulated only in the earlier stages.
With regard to the chondrogenic factors, SOX9 mRNA 
expression was up-regulated in the treated group compared 
to the sham group at 1 week, and remained up-regulated for 
6 weeks. AGG was up-regulated at 1 week and remained 
up-regulated for 3 weeks. The safranin O-stained paraffin-
embedded sections revealed the presence of proteoglycan 
in repaired tissue at 1, 2, 3, and 6 weeks. As such, it seems 
that tissue undergoing repair is more inclined toward chon-
drogenic than tenogenic differentiation. One may speculate 
that this is one of the reasons for the failure of repaired tis-
sue to achieve the characteristics of normal tendons even 
after 20 weeks.
Some growth factors have been reported to promote ten-
don differentiation. Lee et al. [28] noted that brief stimu-
lation with bone morphogenetic protein (BMP) 12 in vitro 
was sufficient to induce the differentiation of bone marrow-
derived mesenchymal stem cells into tenocytes, and that 
this phenotype was sustained in vivo. To date, however, 
no factor has been reported to up-regulate tendon lineage 
differentiation markers or maintain their upregulation for 
longer periods. The inhibition of chondrometaplasia may 
be important in preventing ectopic ossification, as ossifi-
cation appears to emerge from areas of chondrometapla-
sia. Treatment in this case should be initiated in the early 
phase, as chondrometaplasia can be observed beginning in 
the first week of repair. Lui et al. [10, 11] demonstrated the 
presence of chondrometaplasia and ectopic ossification at 
the injury site in a rat collagenase-induced patellar tendon 
window injury model. The authors suggested that errone-
ous differentiation of stem cells may occur in the damaged 
tendon. In our study, RUNX2 mRNA expression was up-
regulated at 2, 3, and 20 weeks, and micro-CT revealed 
ectopic ossification in the treated group after 6 weeks. 
There may be similarities among studies from the perspec-
tive of mechanical stress depreciation [18, 19] or factors 
such as BMPs [29].
This study did have some limitations. First, the num-
ber of samples in our study was small. Therefore, some 
RT-PCR data varied widely, and significance could not be 
demonstrated at some time points. Second, the volume of 
samples was also very small. We did not match the con-
centrations of mRNA in PCR study because some of them 
showed very low concentrations. Efficiencies of the prim-
ers used in this study were rechecked with dilution series 
of some of the cDNA samples, and they were almost iden-
tical to the range of the concentrations used in this study. 
We did not test the suitability of the GAPDH gene to act as 
a true internal standard for the sham-injured group, given 
the limited sample availability. Murphy and Polak reported 
that both HPRT and β-tubulin mRNA levels varied mark-
edly between spontaneously differentiating and growth 
factor-supplemented murine embryonic stem cell cultures, 
Fig. 7  Micro-computed tomography (micro-CT) of the patellae and 
patellar tendons. Patellae are indicated as P. a No ectopic bone was 
detected at 3 weeks. b At 6 weeks, ectopic ossification was detected 
in 2 cases. c, d At 12 and 20 weeks, all tendons had ectopic ossifica-
tion. e Mean volumes of ectopic ossification increased over time
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while GAPDH expression remained relatively constant 
[30]. Although we did not utilize an in vitro study model 
with embryonic stem cells, the situations would appear 
to be similar, as stem cells and growth factors may be 
involved in the formation of repaired tissue, and thus it may 
be reasonable to consider GAPDH as an internal standard. 
Moreover, proteins were not analyzed due to the insuffi-
cient quantity (ten) and volume (just several milligrams) of 
samples. Analysis of proteins may become possible using a 
technique such as mass spectrometry capable of analyzing 
small samples.
In conclusion, some vessels were present in the repaired 
tissue at tendon defect sites even during the later period. 
Tenogenesis appeared to occur only in the early phase, 
while ectopic ossification emerged following chondrometa-
plasia that was maintained from the early phase to the late 
phase. To improve tendon healing, it will be necessary to 
promote tenogenesis and inhibit chondrogenesis (especially 
in the early phase) in order to avoid the erroneous differen-
tiation of stem cells.
Acknowledgments No benefits in any form have been received 
from any commercial party directly related to the subject of this 
article. Funding was supported by the Grants-in-Aid for Scientific 
Research (KAKENHI) 22659271 and 24659672, and the MEISEI-
KAI fund. We sincerely thank Prof. Kawai for permitting us to use the 
R_mCT unit at Aichi Gakuin University, School of Dentistry, Depart-
ment of Dental Materials and Devices.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Wang JH. Mechanobiology of tendon. J Biomech. 2006;39:1563–82.
 2. Dourte LM, Kuntz AF, Soslowsky LJ. Twenty-five years of ten-
don and ligament research. J Orthop Res. 2008;26:1297–305.
 3. Sharma P, Maffulli N. Biology of tendon injury: healing, mod-
eling and remodeling. J Musculoskelet Neuronal Interact. 
2006;6:181–90.
 4. Petersen W, Varoga D, Zantop T, Hassenpflug J, Mentlein R, 
Pufe T. Cyclic strain influences the expression of the vascular 
endothelial growth factor (VEGF) and the hypoxia inducible 
factor 1 alpha (HIF-1alpha) in tendon fibroblasts. J Orthop Res. 
2004;22:847–53.
 5. Boyer MI, Watson JT, Lou J, Manske PR, Gelberman RH, Cai 
SR. Quantitative variation in vascular endothelial growth factor 
mRNA expression during early flexor tendon healing: an investi-
gation in a canine model. J Orthop Res. 2001;19:869–72.
 6. Berglund ME, Hart DA, Reno C, Wiig M. Growth factor and pro-
tease expression during different phases of healing after rabbit 
deep flexor tendon repair. J Orthop Res. 2011;29:886–92.
 7. Molloy T, Wang Y, Murrell G. The roles of growth factors in ten-
don and ligament healing. Sports Med. 2003;33:381–94.
 8. Petersen W, Pufe T, Unterhauser F, Zantop T, Mentlein R, 
Weiler A. The splice variants 120 and 164 of the angiogenic 
peptide vascular endothelial cell growth factor are expressed 
during Achilles tendon healing. Arch Orthop Trauma Surg. 
2003;123:475–80.
 9. Petersen W, Unterhauser F, Pufe T, Zantop T, Südkamp NP, 
Weiler A. The angiogenic peptide vascular endothelial growth 
factor is expressed during the remodeling of free tendon grafts in 
sheep. Arch Orthop Trauma Surg. 2003;123:168–74.
 10. Lui PPY, Fu SC, Chan LS, Hung LK, Chan KM. Chondrocyte 
phenotype and ectopic ossification in collagenase-induced tendon 
degeneration. J Histochem Cytochem. 2009;57:91–100.
 11. Lui PP, Cheuk YC, Lee YW, Chan KM. Ectopic chondro-ossifi-
cation and erroneous extracellular matrix deposition in a tendon 
window injury model. J Orthop Res. 2012;30:37–46.
 12. Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC, Sonoyama 
W, Li L, Leet AI, Seo BM, Zhang L, Shi S, Young MF. Identifica-
tion of tendon stem/progenitor cells and the role of the extracel-
lular matrix in their niche. Nat Med. 2007;13:1219–27.
 13. Cserjesi P, Brown D, Ligon KL, Lyons GE, Copeland NG, Gil-
bert DJ, Jenkins NA, Olson EN. Scleraxis: a basic helix-loop-
helix protein that prefigures skeletal formation during mouse 
embryogenesis. Development. 1995;121:1099–110.
 14. Schweitzer R, Chyung JH, Murtaugh LC, Brent AE, Rosen V, 
Olson EN, Lassar A, Tabin CJ. Analysis of the tendon cell fate 
using Scleraxis, a specific marker for tendons and ligaments. 
Development. 2001;128:3855–66.
 15. Shukunami C, Oshima Y, Hiraki Y. Molecular cloning of tenom-
odulin, a novel chondromodulin-I related gene. Biochem Biophys 
Res Commun. 2001;280:1323–7.
 16. Brandau O, Meindl A, Fässler R, Aszódi A. A novel gene, tendin, 
is strongly expressed in tendons and ligaments and shows high 
homology with chondromodulin-I. Dev Dyn. 2001;221:72–80.
 17. Docheva D, Hunziker EB, Fässler R, Brandau O. Tenomodulin is 
necessary for tenocyte proliferation and tendon maturation. Mol 
Cell Biol. 2005;25:699–705.
 18. Maffulli N, Reaper J, Ewen SW, Waterston SW, Barrass V. Chon-
dral metaplasia in calcific insertional tendinopathy of the Achilles 
tendon. Clin J Sport Med. 2006;16:329–34.
 19. Yokota A, Gimbel JA, Williams GR, Soslowsky LJ. Supraspina-
tus tendon composition remains altered long after tendon detach-
ment. J Shoulder Elbow Surg. 2005;14:S72–8.
 20. Bi WM, Deng JM, Zhang Z, Behringer PR, deCrombrug-
ghe B. Sox9 is required for cartilage formation. Nat Genet. 
1999;22:85–9.
 21. Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya 
K, Nifuji A, Noda M. SOX9 enhances aggrecan gene promoter/
enhancer activity and is up-regulated by retinoic acid in a carti-
lage-derived cell line, TC6. J Biol Chem. 2000;275:10738–44.
 22. Lefebvre V, Huang W, Harley VR, Goodfellow PN, deCrombrug-
ghe B. SOX9 is a potent activator of the chondrocyte-specific 
enhancer of the pro alpha 1(II) collagen gene. Mol Cell Biol. 
1997;17:2336–46.
 23. Pacifici M, Golden EB, Adams SL, Shapiro IM. Cell hypertrophy 
and type X COLLAGEN synthesis in cultured articular chondro-
cytes. Exp Cell Res. 1991;192:266–70.
 24. Prince M, Banerjee C, Javed A, Green J, Lian JB, Stein GS, 
Bodine PVN, Komm BS. Expression and regulation of Runx2/
Cbfa1 and osteoblast phenotypic markers during the growth 
and differentiation of human osteoblasts. J Cell Biochem. 
2001;80:424–40.
 25. Pfaffl MW. A new mathematical model for relative quantification 
in real-time RT-PCR. Nucleic Acids Res. 2001;29:2002–7.
 26. Gerber HP, Ferrara N. Angiogenesis and bone growth. Trends 
Cardiovasc Med. 2000;10:223–8.
 27. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. 
VEGF couples hypertrophic cartilage remodeling, ossification 
389Process of tendon healing
1 3
and angiogenesis during endochondral bone formation. Nat Med. 
1999;5:623–8.
 28. Lee JY, Zhou Z, Taub PJ, Ramcharan M, Li Y, Akinbiyi T, Maha-
ram ER, Leong DJ, Laudier DM, Ruike T, Torina PJ, Zaidi M, 
Majeska RJ, Schaffler MB, Flatow EL, Sun HB. BMP-12 treat-
ment of adult mesenchymal stem cells in vitro augments ten-
don-like tissue formation and defect repair in vivo. PLoS One. 
2011;6:e17531.
 29. Yee Lui PP, Wong YM, Rui YF, Lee YW, Chan LS, Chan KM. 
Expression of chondro-osteogenic BMPs in ossified failed tendon 
healing model of tendinopathy. J Orthop Res. 2011;29:816–21.
 30. Murphy CL, Polak JM. Differentiating embryonic stem cells: 
GAPDH, but neither HPRT nor β-Tubulin is suitable as an internal 
standard for measuring RNA levels. Tissue Eng. 2002;8:551–9.
